Patients experiencing gastroparesis commonly report the following debilitating symptoms: Severe nausea and vomiting: Multiple daily episodes, unable to keep down liquids, leading to dangerous dehydration requiring emergency IV fluids Extreme early satiety: Feeling full after few bites, with food stuck in throat persisting hours Chronic abdominal pain and bloating: Persistent upper abdomen distention interfering with daily activities Dangerous weight loss: Inability to consume adequate calories causing vitamin deficiencies, muscle wasting, requiring feeding tubes Blood sugar fluctuations: Unpredictable glucose with nighttime lows followed by morning highs Diagnosing requires specific testing to measure gastric emptying
Drug compounding is intended to address patient-specific medical needs, such as allergies, a need for a different dosage form, or when the FDA-approved drug is not medically appropriate to treat a particular patient
Continuous GLP-1RA use for three years was associated with the greatest reduction in MACE risk compared with sulfonylureas, whereas interruptions and discontinuations were associated with a progressive attenuation of this protective effect, with risk estimates in some scenarios approaching those of the comparator group
According to a White House statement, the Trump administration sees this historic agreement as an opportunity to "reverse the obesity epidemic and associated chronic disease crisis when coupled with lifestyle changes to preserve and improve health gains long-term." EatingWell senior nutrition editor, Jessica Ball, M.S., RD, offers expert insights for those interested in taking a GLP-1 for weight loss
Patients should not discontinue semaglutide without consulting their healthcare provider unless instructed to do so for safety reasons
In the periphery, GLP-1 agonists enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, and slow gastric emptying
